Our CTO Nick Nystrom was featured in @HealthLeaders. Read the full piece to learn more about his career journey and the difference he hopes to make leveraging his #AI expertise in the #biopharma industry with the Peptilogics team:

We are pleased to report on another milestone of promising interim data for PLG0206 to address the challenging condition of Periprosthetic Joint Infection (PJI).

#PeriprostheticJointInfections are historically difficult to treat. @CARB_X's @RobinPBerghaus examines how Peptilogics is designing #peptide therapeutics to target a range of bacteria impacting patients diagnosed w/ #PJI:

Through the power of #AI & #MachineLearning, researchers can design more efficient #ClinicalTrials for their patient populations. Our Chief Strategy Officer, Atul Deshpande, shares his takeaways from #BIO2023 about this timely topic in @ClinicalLeader1:

This year’s #BIOConvention was filled with lively discussions around advances in clinical research, new technology innovations & more. Our CEO & Founder, Jonathan Steckbeck, shared his biggest takeaways from #BIO23 w/@ClinicalLeader1. Read more here:

We had a productive week at #BIO2023 meeting with industry leaders to discuss the future of #PeptideTherapeutics and using #AI for drug discovery. We even had the pleasure of connecting with #BioTechNation – thank you for taking the time to hear more about our work!

We’re working to change the treatment paradigm of #PeriprostheticJointInfection (PJI). On the latest Business of Biotech podcast, our CEO & Founder, Jonathan Steckbeck, speaks with host @mattpillar about the costs and complexities of managing #PJI:

We are thrilled to unveil the highly promising interim data for PLG0206, a breakthrough therapy specifically designed to address the challenging condition of Periprosthetic Joint Infection (PJI).

The estimated cost for a single episode of care for #PJI typically exceeds $100k & average treatment costs stemming from ongoing clinic visits, frequent hospitalizations & long hospital stays total over $500k. Our CEO discusses this & more in @BioTuesdays:

@Peptilogics’ Nautilus™ generative AI platform is enabling drug discovery across diverse target classes and therapeutic areas. At the Drug Discovery Strategic Summit, CTO @NickNystromPhD will discuss how Nautilus is being applied to design multiparameter-optimized peptide leads.

Pipeline corner presentation at ECCMID on April 15th of PLG0206 will be the first glimpse of safety and efficacy data from its ongoing Ph1b trial in Periprosthetic Joint Infections (PJI). #PJI #enrollment #data #safety #efficacy

Our CTO, Nicholas Nystrom, recently appeared on @iambiotech's I AM BIO podcast to discuss the power of #AI in drug discovery. Tune in to hear how Peptilogics is using AI to accelerate the development of novel #peptide therapeutics:

#ICYMI: Peptilogics Chief Operating Officer, Nick Pachuda recently reflected on his time at @AAOS1 and shared his personal highlights from the conference. #AAOS2023

Next week our team is attending the @AAOS1 Annual Meeting. Let us know you'll be there & would like to connect to learn more about our lead program, PLG0206, a broad-spectrum orthopedic anti-infective #peptide therapeutic being developed for #PeriprostheticJointInfection (#PJI).

Our Chief Technology Officer, Nicholas Nystrom, is speaking at the @hpccouncil 14th Annual Stanford Conference to discuss the use of generative AI to unlock chemical spaces for novel drug design & our #AI #peptide #drugdiscovery platform, #Nautilus. #HPC

Our CEO & Founder, Jonathan Steckbeck, and CSO, Atul Deshpande, are attending the @IAmBiotech #BIOCEO23 Conference. They look forward to connecting w/ potential #investors & #partners to discuss #PJI & our progress w/ PLG0206, a next generation #peptide therapeutic in the clinic.

Our CEO & Founder, Jonathan Steckbeck, was featured in @HealthLeaders. Learn how he created Peptilogics with the goal of revolutionizing the discovery process for novel #peptide therapeutics to help patients with serious & life-threatening diseases:

Our Chief Strategy Officer, Atul Deshpande, was recently featured in the @PharmaScrip Asks Series, sharing insights on how the #biopharma funding environment will evolve in 2023: #ScripAsks

Next week, members of the Peptilogics team will be in #SF taking meetings at the @jpmorgan Annual Healthcare Conference. Reach out if you’d like to learn more about our programs in #PJI, #CF, #ADPKD & our #ML driven designer peptide therapeutics platform, Nautilus. #JPM2023

Our CMO, David Huang, recently met w/ @KarenJagoda, host of Empowered Patient Podcast, to discuss the burden of #PeriprostheticJointInfection and the potential of our #peptide therapeutic PLG0206. Listen to the full episode here: